MedTrace Logo

HeartPhone Cancer Survivors Trial 2019

NCT03953326 · Status: TERMINATED · Phase: PHASE1/PHASE2 · Type: INTERVENTIONAL · Enrollment: 2

Last updated 2026-02-27

Study results available
· View outcomes & findings →

Summary

This is a behavioral study that will examine changes in physical activity and vascular health in response to a digital tool (app) that will appear on participant's lock screen of their Android phone. Participants will be asked to use this app for 3 months and to wear a Fitbit device continuously throughout the study. Participants will be asked to complete questionnaires, participate in fitness testing and measures of cardiovascular health at 3 months and 6 months after baseline assessments. The hypothesis is that exposure to the app will lead to increased physical activity volume and improved microvessel function.

Conditions

Interventions

BEHAVIORAL

HeartPhone app

Evaluative conditioning (temporally distributed micro-doses presented upon activation of smartphone screen)

DRUG

Acetylcholine

Endothelium-dependent vasodilation is tested with the localized delivery of the neurotransmitter

DRUG

Sodium Nitroprusside

Endothelium-independent vasodilation is tested with the localized delivery of the nitric oxide donor

DRUG

L-Arginine, N2-((4-Methylphenyl)Sulfonyl)-, Methyl Ester

This nitric oxide inhibitor is continuously given during the localized delivery of the endothelium-dependent agonist acetycholine.

Sponsors & Collaborators

  • Penn State University

    lead OTHER

Study Design

Allocation
NA
Purpose
PREVENTION
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
18 Years
Max Age
65 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2019-04-23
Primary Completion
2020-12-31
Completion
2020-12-31
FDA Drug
Yes

Countries

  • United States

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT03953326 on ClinicalTrials.gov